A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

I1F-MC-RHBY -

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Axial Spondyloarthritis
What the trial is testing?
Ixekizumab
Could I receive a Placebo?
Yes
Enrollment Goal
773
Trial Dates
May 9, 2017 - May 27, 2021
How long will I be in the trial?
Your participation could last approximately 32 months and include approximately 22 visits to the study center.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have completed either study RHBV (NCT02696785), RHBW (NCT02696798), or RHBX (NCT02757352). NOTE: Participants from study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a tumor necrosis factor [TNF] inhibitor

  • Participant must agree to use a reliable method of birth control

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.